DANBURY, Conn., Sept 24, 2010 /PRNewswire via COMTEX News Network/ -- Biodel Inc. (Nasdaq: BIOD) announced today that it will be presenting at the following upcoming conferences:
About Biodel Inc.
Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for diabetes. Biodel's product candidates are developed using VIAdel(TM) technology, which reformulates existing FDA-approved peptide drugs. Biodel's new drug application for its most advanced product candidate, Linjeta(TM), has been accepted for review by the FDA with a Prescription Drug User Fee Act action date of October 30, 2010. Earlier-stage product candidates include VIAtab(TM), a sublingual tablet formulation of insulin, a line of basal insulins, and a stabilized formulation of glucagon. For further information regarding Biodel, please visit the company's website at www.biodel.com.
CONTACT: Seth Lewis, +1-646-378-2952
SOURCE Biodel Inc.
Copyright (C) 2010 PR Newswire. All rights reserved